Increasing prevalence of diabetes across the globe will be a major factor expanding the global “chronic kidney disease treatment market” in the forthcoming decade. Diabetes damages the small blood vessels all over the body. When the blood vessels in the kidneys get injured, the kidneys are unable to clean the blood properly, resulting in the body retaining excessive amount of water and salts, which then leads to weight gain. Nerve damage caused by diabetes can severely disturb urine functions. For example, bacteria can grow unimpeded and cause infection if you hold urine in the bladder for a long time. More importantly, the incidence of diabetes around the world is rising at a rapid rate. According to the International Diabetes Federation (IDF), presently, there are about 463 million diabetics in the world. The IDF estimates that by 2045, this number will hit 700 million, given the unhealthy lifestyles majority of the people are leading today. Thus, steady diffusion of diabetes among the world populace will spike the demand for effective treatments for chronic kidney disease.
In its recent report, titled “Chronic Kidney Disease Treatment Market Size, Share and Global Trend By Type of Treatment (Drugs, Dialysis, Transplantation of Kidneys, Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centres (ASCs), Dialysis Centers, Others), and Geography Forecast till 2026”, Fortune Business Insights™ shares the following:
- Careful segregation of the market into segments and piece-meal analysis of each segment;
- Thorough assessment of the various market drivers and challenges;
- In-depth research into the regional and competitive dynamics; and
- Accurate computation of market figures (size, share, revenue, etc.).
Request a Sample Copy of the Research Report:
Asia-Pacific to Boast an Impressive CAGR; North America to Dominate
Among regions, North America is slated to command the chronic kidney disease treatment market share during the forecast period owing to rising prevalence of kidney diseases in the US. As per the statistics of the Centers for Disease Control and Prevention (CDC), approximately 15%, or 30 million, of Americans were suffering from chronic kidney conditions in 2017. In Asia-Pacific, the market is anticipated to grow at a considerable CAGR on account of speedy spread of chronic disorders and aggressive government-led initiatives to make healthcare accessible to all sections of society.
Growth in Global Geriatric Population to Fuel the Market
World population is ageing at an astonishing rate and old people typically suffer from complicated health disorders. Chronic kidney disease is one such disorder that is generally prevalent among the geriatric population owing to the high risk factors such as hypertension and cardiovascular conditions within this demographic. The UN’s Department of Economic and Social Affairs (DESA) estimates that currently the world is home to 962 million people aged 60 and above; by 2050, the number of old people will cross the billion mark to reach 2.1 billion. More significantly, the DESA predicts that by 2030, aged people will outpace the number of children below the age of 10. This means that kidney disorders are likely spike in the next few decades, with the World Health Organization projecting that around 5.24 million people worldwide will receive dialysis by 2030. Since chronic conditions entail a huge economic burden, the demand for treatments and drugs for kidney disorders will surge in the upcoming years and lead the chronic kidney disease treatment market trends.
Regulatory Approvals to Encourage Innovation Among Competitors
“Timely regulatory clearances to novel therapies will fire up innovation energies in key players”, says a lead analyst at Fortune Business Insights™. According to the chronic kidney disease market analysis, development of advanced treatment options will aid companies deepen their presence in this market and even enable them to expand geographically.
August 2019: GlaxoSmithKline submitted an application to the Japanese Ministry of Health, Labor and Welfare to market daprodustat in the country. The product is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat patients suffering from renal anemia caused by chronic kidney disease.
March 2019: Johnson & Johnson’s Janssen Pharmaceutical Companies submitted a new application to the US FDA for the approval of its supplemental drug, INVOKANA®. The drug is developed to treat chronic kidney disease in patients having type 2 diabetes and its efficacy was successfully tested by the company in the Phase 3 of its CREDENCE clinical study.
Top manufactures of Chronic Kidney Disease Treatment Market are:
- Johnson & Johnson
- Allergan plc.
- AbbVie, Inc.
- Pfizer, Inc.
- Sanofi S.A.
- GlaxoSmithKline plc.
- FibroGen Inc.
- Keryx Biopharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd.
- AstraZeneca plc
- Teva Pharmaceutical Industries Ltd.
- Hoffmann-La Roche Ltd.
- Amgen Inc.
Segmentation of the Global Chronic Kidney Disease Treatment Market
By Type of Treatment
- ACE Inhibitors
- Angiotensin-II receptor Blockers
- Calcium channel Blockers
- Erythropoiesis-stimulating Agents (ESAs)
- Transplantation of Kidneys
By End User
- Hospitals & Clinics
- Ambulatory Surgery Centres (ASCs)
- Dialysis Centres
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/chronic-kidney-disease-treatment-market-100694
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245